TP53 and Hodgkins lymphoma: The ISKS cohort is being systematically screened for mutations in the TP53 gene (manuscript in preparation) and 3 of the 16 probands in the HL families (including one who had both a sarcoma and HL) were positive for germline mutations in TP53 (19%).